Skip to main content
Erschienen in: Drugs & Aging 10/2010

01.10.2010 | Original Research Article

Changes in Under-Treatment after Comprehensive Geriatric Assessment

An Observational Study

verfasst von: Dr Linda R. Tulner, Jos P. C. M. van Campen, Suzanne V. Frankfort, Cornelis H. W. Koks, Jos H. Beijnen, Desiderius P. M. Brandjes, Paul A. F. Jansen

Erschienen in: Drugs & Aging | Ausgabe 10/2010

Einloggen, um Zugang zu erhalten

Abstract

Background Under-treatment is frequently present in geriatric patients. Because this patient group often suffer from multiple diseases, polypharmacy (defined as the concomitant chronic use of five or more drugs) and contraindications to indicated drugs may also frequently be present.
Objective To describe the prevalence of under-treatment with respect to frequently indicated medications before and after comprehensive geriatric assessment (CGA) and the prevalence of contraindications to these medications.
Patients and Methods The geriatric outpatients evaluated in this study had previously been included in a prospective descriptive study conducted in 2004. Demographic data, medical history, co-morbidity and medication use and changes were documented. The absence of drugs indicated for frequently under-treated conditions before and after CGA was compared. Under-treatment was defined as omission of drug therapy indicated for the treatment or prevention of 13 established diseases or conditions known to be frequently under-treated. Co-morbid conditions were independently classified by two geriatricians, who determined whether or not a condition represented a contraindication to use of these drugs.
Results In 2004, 807 geriatric outpatients were referred for CGA. Of these, 548 patients had at least one of the 13 selected diseases or conditions. Thirty-two of these patients were excluded from the analysis, leaving 516 patients. Before CGA, 170 of these patients were under-treated (32.9%); after CGA, 115 patients (22.3%) were under-treated. Contraindications were present in 102 of the patients (19.8%) and were more frequent in under-treated patients. After CGA, mean drug use and the prevalence of polypharmacy increased. Although 393 drugs were discontinued after CGA, the overall number of drugs used increased from 3177 before CGA to 3424 after CGA. Five times more drugs were initiated for a new diagnosis than for correction of under-treatment.
Conclusions Under-treatment is significantly reduced after CGA. Patients with contraindications to indicated medicines are more frequently under-treated. CGA leads to an increase in polypharmacy, mainly because of new conditions being diagnosed and despite frequent discontinuation of medications.
Literatur
1.
Zurück zum Zitat Rochon PA, Gurwitz JH. Prescribing for seniors: neither too much nor too little. JAMA 1999; 281(2): 113–5CrossRef Rochon PA, Gurwitz JH. Prescribing for seniors: neither too much nor too little. JAMA 1999; 281(2): 113–5CrossRef
2.
Zurück zum Zitat Steinman MA, Landefeld CS, Rosenthal GE, et al. Polypharmacy and prescribing quality in older people. J Am Geriatr Soc 2006; 54: 1516–23PubMedCrossRef Steinman MA, Landefeld CS, Rosenthal GE, et al. Polypharmacy and prescribing quality in older people. J Am Geriatr Soc 2006; 54: 1516–23PubMedCrossRef
3.
Zurück zum Zitat Denneboom W, Dautzenberg MGH, Grol R, et al. Analysis of polypharmacy in older patients in primary care using a multidisciplinary expert panel. Br J Gen Pract 2006; 56: 504–10PubMed Denneboom W, Dautzenberg MGH, Grol R, et al. Analysis of polypharmacy in older patients in primary care using a multidisciplinary expert panel. Br J Gen Pract 2006; 56: 504–10PubMed
4.
Zurück zum Zitat Kuijpers MA, van Marum RJ, Egberts AC, et al. Relationship between polypharmacy and underprescribing. Br J Clin Pharmacol 2008; 65(1): 130–3PubMedCrossRef Kuijpers MA, van Marum RJ, Egberts AC, et al. Relationship between polypharmacy and underprescribing. Br J Clin Pharmacol 2008; 65(1): 130–3PubMedCrossRef
5.
Zurück zum Zitat Ko DT, Mamdani M, Alter DA. Lipid-lowering therapy with statins in high-risk elderly patients: the treatment-risk paradox. JAMA 2004; 291: 1864–70PubMedCrossRef Ko DT, Mamdani M, Alter DA. Lipid-lowering therapy with statins in high-risk elderly patients: the treatment-risk paradox. JAMA 2004; 291: 1864–70PubMedCrossRef
6.
Zurück zum Zitat Havranek EP, Abrams F, Stevens E, et al. Determinants of mortality in elderly patients with heart failure: the role of angiotensin-converting enzyme inhibitors. Arch Intern Med 1998; 158: 2024–8PubMedCrossRef Havranek EP, Abrams F, Stevens E, et al. Determinants of mortality in elderly patients with heart failure: the role of angiotensin-converting enzyme inhibitors. Arch Intern Med 1998; 158: 2024–8PubMedCrossRef
7.
Zurück zum Zitat Soumerai SB, McLaughlin TJ, Spiegelman D, et al. Adverse outcomes of underuse of beta-blockers in elderly survivors of acute myocardial infarction. JAMA 1997; 277: 115–21PubMedCrossRef Soumerai SB, McLaughlin TJ, Spiegelman D, et al. Adverse outcomes of underuse of beta-blockers in elderly survivors of acute myocardial infarction. JAMA 1997; 277: 115–21PubMedCrossRef
8.
Zurück zum Zitat Kuzuya M, Masuda Y, Hirakawa Y, et al. Underuse of medications for chronic disease in the oldest of community-dwelling older frail Japanese. J Am Geriatr Soc 2006; 54: 598–05PubMedCrossRef Kuzuya M, Masuda Y, Hirakawa Y, et al. Underuse of medications for chronic disease in the oldest of community-dwelling older frail Japanese. J Am Geriatr Soc 2006; 54: 598–05PubMedCrossRef
9.
Zurück zum Zitat Komajda M, Follath F, Swedberg K, et al., on behalf of the Study Group on Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology. The EuroHeart Failure Survey programme: a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Eur Heart J 2003; 24: 464–74PubMedCrossRef Komajda M, Follath F, Swedberg K, et al., on behalf of the Study Group on Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology. The EuroHeart Failure Survey programme: a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Eur Heart J 2003; 24: 464–74PubMedCrossRef
10.
Zurück zum Zitat Boyles PJ, Peterson GM, Bleasel MD, et al. Undertreatment of congestive heart failure in an Australian setting. J Clin Pharm Ther 2004; 29: 15–22PubMedCrossRef Boyles PJ, Peterson GM, Bleasel MD, et al. Undertreatment of congestive heart failure in an Australian setting. J Clin Pharm Ther 2004; 29: 15–22PubMedCrossRef
11.
Zurück zum Zitat Tran CT, Laupacis A, Mamdani MM, et al. Effect of age on the use of evidence-based therapies for acute myocardial infarction. Am Heart J 2004; 148(5): 834–41PubMedCrossRef Tran CT, Laupacis A, Mamdani MM, et al. Effect of age on the use of evidence-based therapies for acute myocardial infarction. Am Heart J 2004; 148(5): 834–41PubMedCrossRef
12.
Zurück zum Zitat Higashi T, Shekelle PG, Solomon DH, et al. The quality of pharmacological care for vulnerable older patients. Ann Intern Med 2004; 140: 714–20PubMed Higashi T, Shekelle PG, Solomon DH, et al. The quality of pharmacological care for vulnerable older patients. Ann Intern Med 2004; 140: 714–20PubMed
13.
Zurück zum Zitat Boyd CM, Darer J, Boult C, et al. Clinical practice guidelines and quality of care for older patients with multiple comorbid conditions: implications for pay for performance. JAMA 2005; 294: 716–24PubMedCrossRef Boyd CM, Darer J, Boult C, et al. Clinical practice guidelines and quality of care for older patients with multiple comorbid conditions: implications for pay for performance. JAMA 2005; 294: 716–24PubMedCrossRef
14.
Zurück zum Zitat Baker DW, Hayes RP, Massie BM, et al. Variations in family physicians’ and cardiologists’ care for patients with heart failure. Am Heart J 1999; 138: 826–34PubMedCrossRef Baker DW, Hayes RP, Massie BM, et al. Variations in family physicians’ and cardiologists’ care for patients with heart failure. Am Heart J 1999; 138: 826–34PubMedCrossRef
15.
Zurück zum Zitat Lipton HL, Bero LA, Bird JA, et al. Undermedication among geriatric outpatients: results of a randomized controlled trial. Ann Rev Gerontol Ger 1992; 12: 95–108 Lipton HL, Bero LA, Bird JA, et al. Undermedication among geriatric outpatients: results of a randomized controlled trial. Ann Rev Gerontol Ger 1992; 12: 95–108
16.
Zurück zum Zitat Lee DS, Tu JV, Juurlink DN, et al. Risk-treatment mismatch in the pharmacotherapy of heart failure. JAMA 2005; 294: 1240–7PubMedCrossRef Lee DS, Tu JV, Juurlink DN, et al. Risk-treatment mismatch in the pharmacotherapy of heart failure. JAMA 2005; 294: 1240–7PubMedCrossRef
17.
Zurück zum Zitat Schmader KE, Hanlon JT, Pieper CF, et al. Effects of geriatric evaluation and management on adverse drug reactions and suboptimal prescribing in the frail elderly. Am J Med 2004; 116: 394–401PubMedCrossRef Schmader KE, Hanlon JT, Pieper CF, et al. Effects of geriatric evaluation and management on adverse drug reactions and suboptimal prescribing in the frail elderly. Am J Med 2004; 116: 394–401PubMedCrossRef
18.
Zurück zum Zitat Tulner LR, Frankfort SV, Gijsen GJ, et al. Drug-drug interactions in a geriatric outpatient cohort: prevalence and relevance. Drugs Aging 2008; 25(4): 343–55PubMedCrossRef Tulner LR, Frankfort SV, Gijsen GJ, et al. Drug-drug interactions in a geriatric outpatient cohort: prevalence and relevance. Drugs Aging 2008; 25(4): 343–55PubMedCrossRef
19.
Zurück zum Zitat Folstein MF, Folstein SE, McHugh PR. “Mini-Mental State”: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189–98PubMedCrossRef Folstein MF, Folstein SE, McHugh PR. “Mini-Mental State”: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189–98PubMedCrossRef
20.
Zurück zum Zitat Meulen EF, Schmand B, van Campen JP, et al. The seven minute screen: a neurocognitive screening test highly sensitive to various types of dementia. J Neurol Neurosurg Psychiatry 2004; 75(5): 700–5PubMedCrossRef Meulen EF, Schmand B, van Campen JP, et al. The seven minute screen: a neurocognitive screening test highly sensitive to various types of dementia. J Neurol Neurosurg Psychiatry 2004; 75(5): 700–5PubMedCrossRef
21.
Zurück zum Zitat Mahoney FI, Barthel DW. Functional evaluation: the Barthel Index. Maryland State Med J 1965; 14: 61–5 Mahoney FI, Barthel DW. Functional evaluation: the Barthel Index. Maryland State Med J 1965; 14: 61–5
22.
Zurück zum Zitat Fillenbaum GG. Screening the elderly: a brief instrumental activities of daily living measure. J Am Geriatr Soc 1985; 33: 698–706PubMed Fillenbaum GG. Screening the elderly: a brief instrumental activities of daily living measure. J Am Geriatr Soc 1985; 33: 698–706PubMed
23.
Zurück zum Zitat Samsa GP, Hanlon JT, Schmader KE. A summated score for the Medication Appropriateness Index: development and assessment of clinimetric properties including content validity. J Clin Epidemiol 1994; 47: 891–6PubMedCrossRef Samsa GP, Hanlon JT, Schmader KE. A summated score for the Medication Appropriateness Index: development and assessment of clinimetric properties including content validity. J Clin Epidemiol 1994; 47: 891–6PubMedCrossRef
24.
Zurück zum Zitat Charlson ME, Pompei P, Ales KA, et al. A new method of classifying prognostic comorbidity in longitudinal studies. J Chron Dis 1987; 40(5): 373–83PubMedCrossRef Charlson ME, Pompei P, Ales KA, et al. A new method of classifying prognostic comorbidity in longitudinal studies. J Chron Dis 1987; 40(5): 373–83PubMedCrossRef
27.
Zurück zum Zitat Limburg M, Tuut MK. CBO guideline ‘Stroke’ (revision) Dutch Institute for Healthcare Improvement [in Dutch]. Ned Tijdschr Geneeskd 2000 May 27; 144(22): 1058–62PubMed Limburg M, Tuut MK. CBO guideline ‘Stroke’ (revision) Dutch Institute for Healthcare Improvement [in Dutch]. Ned Tijdschr Geneeskd 2000 May 27; 144(22): 1058–62PubMed
28.
Zurück zum Zitat Williams MA, Fleg JL, Ades A, et al. Secondary prevention of coronary heart disease in the elderly (with emphasis on patients ≥75 years of age): an American Heart Association scientific statement from the Council on Clinical Cardiology Subcommittee on Exercise, Cardiac Rehabilitation, and Prevention. Circulation 2002; 105: 1735–43PubMedCrossRef Williams MA, Fleg JL, Ades A, et al. Secondary prevention of coronary heart disease in the elderly (with emphasis on patients ≥75 years of age): an American Heart Association scientific statement from the Council on Clinical Cardiology Subcommittee on Exercise, Cardiac Rehabilitation, and Prevention. Circulation 2002; 105: 1735–43PubMedCrossRef
29.
Zurück zum Zitat Frankfort SV, Tulner CR, van Campen JPCM, et al. Evaluation of pharmacotherapy in geriatric patients after performing complete geriatric assessment (CGA) at a diagnostic day clinic. Clin Drug Invest 2006; 26: 169–74CrossRef Frankfort SV, Tulner CR, van Campen JPCM, et al. Evaluation of pharmacotherapy in geriatric patients after performing complete geriatric assessment (CGA) at a diagnostic day clinic. Clin Drug Invest 2006; 26: 169–74CrossRef
30.
Zurück zum Zitat Go AS, Hylek EM, Chang Y, et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA 2003; 290: 2685–92PubMedCrossRef Go AS, Hylek EM, Chang Y, et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA 2003; 290: 2685–92PubMedCrossRef
31.
Zurück zum Zitat Man-Son-Hing M, Nichol G, Lau A, et al. Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. Arch Intern Med 1999; 159: 677–85PubMedCrossRef Man-Son-Hing M, Nichol G, Lau A, et al. Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. Arch Intern Med 1999; 159: 677–85PubMedCrossRef
33.
Zurück zum Zitat Gage BF, Birman Deych E, Kerzner R, et al. Incidence of intracranial hemorrhage in patients with atrial fibrillation who are prone to fall. Am J Med 2005; 118: 612–7PubMedCrossRef Gage BF, Birman Deych E, Kerzner R, et al. Incidence of intracranial hemorrhage in patients with atrial fibrillation who are prone to fall. Am J Med 2005; 118: 612–7PubMedCrossRef
34.
Zurück zum Zitat Ueno H, Ohshita T, Kondo K, et al. Association between microbleeds on T3*-weighted images and recurrent hemorrhagic stroke in patients treated with warfarin following ischemic stroke. Am J Neuroradiol 2008; 29(8): 1483–6PubMedCrossRef Ueno H, Ohshita T, Kondo K, et al. Association between microbleeds on T3*-weighted images and recurrent hemorrhagic stroke in patients treated with warfarin following ischemic stroke. Am J Neuroradiol 2008; 29(8): 1483–6PubMedCrossRef
35.
Zurück zum Zitat Lee SH, Ryu WS, Roh JK. Cerebral microbleeds are a risk factor for warfarin related intracerebral hemorrhage. Neurology 2009; 72: 171–6PubMedCrossRef Lee SH, Ryu WS, Roh JK. Cerebral microbleeds are a risk factor for warfarin related intracerebral hemorrhage. Neurology 2009; 72: 171–6PubMedCrossRef
36.
Zurück zum Zitat Cordonnier C, van der Flier WM, Sluimer JD, et al. Prevalence and severity of microbleeds in a memory clinic setting. Neurology 2006; 66: 1356–60PubMedCrossRef Cordonnier C, van der Flier WM, Sluimer JD, et al. Prevalence and severity of microbleeds in a memory clinic setting. Neurology 2006; 66: 1356–60PubMedCrossRef
37.
Zurück zum Zitat van Deelen BAJ, van den Beemt PMLA, Egberts TCG, et al. Cognitive impairment as determinant for sub-optimal control of oral anticoagulation treatment in elderly patients with atrial fibrillation. Drugs Aging 2005; 22(4): 353–60PubMedCrossRef van Deelen BAJ, van den Beemt PMLA, Egberts TCG, et al. Cognitive impairment as determinant for sub-optimal control of oral anticoagulation treatment in elderly patients with atrial fibrillation. Drugs Aging 2005; 22(4): 353–60PubMedCrossRef
38.
Zurück zum Zitat Kagansky N, Knobler H, Rimon E, et al. Safety of anticoagulation therapy in well-informed older patients. Arch Intern Med 2004; 164: 2044–50PubMedCrossRef Kagansky N, Knobler H, Rimon E, et al. Safety of anticoagulation therapy in well-informed older patients. Arch Intern Med 2004; 164: 2044–50PubMedCrossRef
39.
Zurück zum Zitat AD 2000 Collaborative group, Bentham P, Gray R, et al. Aspirin in Alzheimer’s disease: a randomized open-label trial. Lancet Neurol 2008; 7(1): 41–9PubMedCrossRef AD 2000 Collaborative group, Bentham P, Gray R, et al. Aspirin in Alzheimer’s disease: a randomized open-label trial. Lancet Neurol 2008; 7(1): 41–9PubMedCrossRef
40.
Zurück zum Zitat Mant J, Hobbs R, Fletcher K, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged study, BAFTA): a randomised controlled trial. Lancet 2007; 370: 493–503PubMedCrossRef Mant J, Hobbs R, Fletcher K, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged study, BAFTA): a randomised controlled trial. Lancet 2007; 370: 493–503PubMedCrossRef
41.
Zurück zum Zitat Goldberger JJ, Bonow RO, Cuffe M, et al. Post-myocardial infarction β-blocker therapy — the bradycardia conundrum: rationale and design for the Pacemaker and β-blocker therapy post-MI (PACE-MI) trial. Am Heart J 2008; 155: 455–64PubMedCrossRef Goldberger JJ, Bonow RO, Cuffe M, et al. Post-myocardial infarction β-blocker therapy — the bradycardia conundrum: rationale and design for the Pacemaker and β-blocker therapy post-MI (PACE-MI) trial. Am Heart J 2008; 155: 455–64PubMedCrossRef
42.
Zurück zum Zitat Andrus MR, Loyed JV. Use of β-adrenoreceptor antagonists in older patients with chronic obstructive pulmonary disease and cardiovascular co-morbidity: safety issues. Drugs Aging 2008; 25(2): 131–44PubMedCrossRef Andrus MR, Loyed JV. Use of β-adrenoreceptor antagonists in older patients with chronic obstructive pulmonary disease and cardiovascular co-morbidity: safety issues. Drugs Aging 2008; 25(2): 131–44PubMedCrossRef
43.
Zurück zum Zitat Gislason GH, Rasmussen JN, Abildstrom SZ, et al. Long-term compliance with beta blockers, angiotensinconverting enzyme inhibitors, and statins after acute myocardial infarction. Eur Heart J 2006; 27: 1153–8PubMedCrossRef Gislason GH, Rasmussen JN, Abildstrom SZ, et al. Long-term compliance with beta blockers, angiotensinconverting enzyme inhibitors, and statins after acute myocardial infarction. Eur Heart J 2006; 27: 1153–8PubMedCrossRef
44.
Zurück zum Zitat Gallagher P, Ryan C, Byrne S, et al. STOPP (Screening Tool for Older Person’s Prescriptions) and START (Screening Tool to Alert doctors to Right Treatment): consensus validation. Int J Clin Pharmacol Ther 2008; 46: 72–83PubMed Gallagher P, Ryan C, Byrne S, et al. STOPP (Screening Tool for Older Person’s Prescriptions) and START (Screening Tool to Alert doctors to Right Treatment): consensus validation. Int J Clin Pharmacol Ther 2008; 46: 72–83PubMed
45.
Zurück zum Zitat Ryan C, O’Mahony D, Kennedy J, et al. Potentially inappropriate prescribing in an Irish elderly population in primary care. Br J Clin Pharmacol 2009; 68(6): 936–47PubMedCrossRef Ryan C, O’Mahony D, Kennedy J, et al. Potentially inappropriate prescribing in an Irish elderly population in primary care. Br J Clin Pharmacol 2009; 68(6): 936–47PubMedCrossRef
46.
Zurück zum Zitat Drenth-van Maanen AC, van Marum RJ, Knol W, et al. Prescribing optimization method for improving prescribing in elderly patients receiving polypharmacy: results of application to case histories by general practitioners. Drugs Aging 2009; 26(8): 687–701PubMedCrossRef Drenth-van Maanen AC, van Marum RJ, Knol W, et al. Prescribing optimization method for improving prescribing in elderly patients receiving polypharmacy: results of application to case histories by general practitioners. Drugs Aging 2009; 26(8): 687–701PubMedCrossRef
Metadaten
Titel
Changes in Under-Treatment after Comprehensive Geriatric Assessment
An Observational Study
verfasst von
Dr Linda R. Tulner
Jos P. C. M. van Campen
Suzanne V. Frankfort
Cornelis H. W. Koks
Jos H. Beijnen
Desiderius P. M. Brandjes
Paul A. F. Jansen
Publikationsdatum
01.10.2010
Verlag
Springer International Publishing
Erschienen in
Drugs & Aging / Ausgabe 10/2010
Print ISSN: 1170-229X
Elektronische ISSN: 1179-1969
DOI
https://doi.org/10.2165/11539330-000000000-00000

Weitere Artikel der Ausgabe 10/2010

Drugs & Aging 10/2010 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.